Skip to main content
Erschienen in: Medical Oncology 5/2018

01.05.2018 | Original Paper

Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT

verfasst von: V. Dell’Acqua, J. Kobiela, F. Kraja, M. C. Leonardi, A. Surgo, M. A. Zerella, S. Arculeo, C. Fodor, R. Ricotti, M. G. Zampino, S. Ravenda, G. Spinoglio, R. Biffi, A. Bazani, R. Luraschi, S. Vigorito, P. Spychalski, R. Orecchia, R. Glynne-Jones, B. A. Jereczek-Fossa

Erschienen in: Medical Oncology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Intensity-modulated radiotherapy (IMRT) is considered the preferred option in squamous cell canal cancer (SCAC), delivering high doses to tumor volumes while minimizing dose to surrounding normal tissues. IMRT has steep dose gradients, but the technique is more demanding as deep understanding of target structures is required. To evaluate genital marginal failure in a cohort of patients with non-metastatic SCAC treated either with IMRT or 3DCRT and concurrent chemotherapy, 117 patients with SCAC were evaluated: 64 and 53 patients were treated with IMRT and 3DCRT techniques, respectively. All patients underwent clinical and radiological examination during their follow-up. Tumor response was evaluated with response evaluation criteria in solid tumors v1.1 guideline on regular basis. All patients’ data were analyzed, and patients with marginal failure were identified. Concomitant chemotherapy was administered in 97 and 77.4% of patients in the IMRT and 3DCRT groups, respectively. In the IMRT group, the median follow-up was 25 months (range 6–78). Progressive disease was registered in 15.6% of patients; infield recurrence, distant recurrence and both infield recurrence and distant recurrence were identified in 5, 4 and 1 patient, respectively. Two out of 64 patients (3.1%) had marginal failures, localized at vagina/recto-vaginal septum and left perineal region. In the 3DCRT group, the median follow-up was 71.3 months (range 6–194 months). Two out of 53 patients (3.8%) had marginal failures, localized at recto-vaginal septum and perigenital structures. The rate of marginal failures was comparable in IMRT and 3DCRT groups (χ2 test p = 0.85). In this series, the use of IMRT for the treatment of SCAC did not increase the rate of marginal failures offering improved dose conformity to the target. Dose constraints should be applied with caution—particularly in females with involvement of the vagina or the vaginal septum.
Literatur
1.
Zurück zum Zitat Vinayan A, Glynne-Jones R. Anal cancer—What is the optimum chemoradiotherapy? Best Pract Res Clin Gastroenterol. 2016;30(4):641–53.CrossRefPubMed Vinayan A, Glynne-Jones R. Anal cancer—What is the optimum chemoradiotherapy? Best Pract Res Clin Gastroenterol. 2016;30(4):641–53.CrossRefPubMed
2.
Zurück zum Zitat Esiashvili N, Landry J, Matthews RH. Carcinoma of the anus: strategies in management. Oncologist. 2002;7(3):188–99.CrossRefPubMed Esiashvili N, Landry J, Matthews RH. Carcinoma of the anus: strategies in management. Oncologist. 2002;7(3):188–99.CrossRefPubMed
3.
Zurück zum Zitat Mitchell MP, Abboud M, Eng C, Beddar AS, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014;37(5):461–6.CrossRefPubMed Mitchell MP, Abboud M, Eng C, Beddar AS, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014;37(5):461–6.CrossRefPubMed
4.
Zurück zum Zitat Call JA, Prendergast BM, Jensen LG, et al. Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study. Am J Clin Oncol. 2016;39(1):8–12.CrossRefPubMed Call JA, Prendergast BM, Jensen LG, et al. Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study. Am J Clin Oncol. 2016;39(1):8–12.CrossRefPubMed
5.
Zurück zum Zitat Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33.CrossRefPubMed Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33.CrossRefPubMed
6.
Zurück zum Zitat Han K, Cummings BJ, Lindsay P, et al. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Int J Radiat Oncol Biol Phys. 2014;90(3):587–94.CrossRefPubMed Han K, Cummings BJ, Lindsay P, et al. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Int J Radiat Oncol Biol Phys. 2014;90(3):587–94.CrossRefPubMed
7.
Zurück zum Zitat Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354–61.CrossRefPubMed Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354–61.CrossRefPubMed
8.
Zurück zum Zitat Menkarios C, Azria D, Laliberté B, et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol. 2007;15(2):41.CrossRef Menkarios C, Azria D, Laliberté B, et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol. 2007;15(2):41.CrossRef
9.
Zurück zum Zitat Brooks CJ, Lee YK, Aitken K, et al. Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol). 2013;25(3):155–61.CrossRef Brooks CJ, Lee YK, Aitken K, et al. Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol). 2013;25(3):155–61.CrossRef
10.
Zurück zum Zitat Zimmermann M, Beer J, Bodis S, et al. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. Acta Oncol. 2017;30:1–7. Zimmermann M, Beer J, Bodis S, et al. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. Acta Oncol. 2017;30:1–7.
11.
Zurück zum Zitat Koeck J, Lohr F, Buergy D, et al. Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer. Radiat Oncol. 2016;4(11):53.CrossRef Koeck J, Lohr F, Buergy D, et al. Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer. Radiat Oncol. 2016;4(11):53.CrossRef
12.
Zurück zum Zitat Mai S, Welzel G, Ottstadt M, et al. Prognostic relevance of HPV infection and p16 overexpression in squamous cell anal cancer. Int J Radiat Oncol Biol Phys. 2015;93(4):819–27.CrossRefPubMed Mai S, Welzel G, Ottstadt M, et al. Prognostic relevance of HPV infection and p16 overexpression in squamous cell anal cancer. Int J Radiat Oncol Biol Phys. 2015;93(4):819–27.CrossRefPubMed
13.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
14.
Zurück zum Zitat Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2000;46(5):1117–26.CrossRefPubMed Dawson LA, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2000;46(5):1117–26.CrossRefPubMed
15.
Zurück zum Zitat Ng M, Leong T, Chander S, Chu J, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455–62.CrossRefPubMed Ng M, Leong T, Chander S, Chu J, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455–62.CrossRefPubMed
16.
Zurück zum Zitat Viswanathan AN, Moughan J, Miller BE, et al. NRG Oncology/RTOG 0921: a phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015;121(13):2156–63.CrossRefPubMedPubMedCentral Viswanathan AN, Moughan J, Miller BE, et al. NRG Oncology/RTOG 0921: a phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015;121(13):2156–63.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat The International Commission on radiation units and measurements, ICRU report no. 83. Prescribing, recording and reporting photon-beam intensity modulated radiation therapy (IMRT). J ICRU. 2010;10(1) report 83. Oxford University Press. https://doi.org/10.1093/jicru/ndq001. The International Commission on radiation units and measurements, ICRU report no. 83. Prescribing, recording and reporting photon-beam intensity modulated radiation therapy (IMRT). J ICRU. 2010;10(1) report 83. Oxford University Press. https://​doi.​org/​10.​1093/​jicru/​ndq001.
18.
Zurück zum Zitat Salati SA, Al Kadi A. Anal cancer—a review. Int J Health Sci (Qassim). 2012;6(2):206–30.CrossRef Salati SA, Al Kadi A. Anal cancer—a review. Int J Health Sci (Qassim). 2012;6(2):206–30.CrossRef
19.
Zurück zum Zitat Haddock MG, Martenson JA. Chapter 39: anal carcinoma. In: Gunderson LL, Tepper JE, editors. Clinical radiation oncology. Pennsylvania: Churchill Livingstone; 2000. p. 747–61. Haddock MG, Martenson JA. Chapter 39: anal carcinoma. In: Gunderson LL, Tepper JE, editors. Clinical radiation oncology. Pennsylvania: Churchill Livingstone; 2000. p. 747–61.
20.
Zurück zum Zitat Vuong T, Devic S, Belliveau P, et al. Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys. 2003;56(3):823–31.CrossRefPubMed Vuong T, Devic S, Belliveau P, et al. Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys. 2003;56(3):823–31.CrossRefPubMed
21.
Zurück zum Zitat Beriwal S, Heron DE, Kim H, et al. Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. Int J Radiat Oncol Biol Phys. 2006;64(5):1395–400.CrossRefPubMed Beriwal S, Heron DE, Kim H, et al. Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. Int J Radiat Oncol Biol Phys. 2006;64(5):1395–400.CrossRefPubMed
22.
Zurück zum Zitat Brooks C, Hansen VN, Riddell A, et al. Proposed genitalia contouring guidelines in anal cancer intensity-modulated radiotherapy. Br J Radiol. 2015;88(1051):20150032.CrossRefPubMedPubMedCentral Brooks C, Hansen VN, Riddell A, et al. Proposed genitalia contouring guidelines in anal cancer intensity-modulated radiotherapy. Br J Radiol. 2015;88(1051):20150032.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Chen AM, Farwell DG, Luu Q, et al. Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1423–9.CrossRefPubMed Chen AM, Farwell DG, Luu Q, et al. Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1423–9.CrossRefPubMed
24.
Zurück zum Zitat Franco P, Arcadipane F, Ragona R, et al. Locally advanced (T3–T4 or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36(4):2027–32.PubMed Franco P, Arcadipane F, Ragona R, et al. Locally advanced (T3–T4 or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36(4):2027–32.PubMed
25.
Zurück zum Zitat Franco P, Arcadipane F, Ragona R, et al. Early-stage node-negative (T1-T2N0) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36(4):1943–8.PubMed Franco P, Arcadipane F, Ragona R, et al. Early-stage node-negative (T1-T2N0) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36(4):1943–8.PubMed
26.
Zurück zum Zitat Bagshaw HP, Sause WT, Gawlick U, et al. Vulvar recurrences after intensity-modulated radiation therapy for squamous cell carcinoma of the anus. Am J Clin Oncol. 2016. [Epub ahead of print]. Bagshaw HP, Sause WT, Gawlick U, et al. Vulvar recurrences after intensity-modulated radiation therapy for squamous cell carcinoma of the anus. Am J Clin Oncol. 2016. [Epub ahead of print].
27.
Zurück zum Zitat Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800.CrossRefPubMed Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800.CrossRefPubMed
28.
Zurück zum Zitat Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on radiation therapy oncology group study no. 8314. J Natl Cancer Inst. 1989;81(11):850–6.CrossRefPubMed Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on radiation therapy oncology group study no. 8314. J Natl Cancer Inst. 1989;81(11):850–6.CrossRefPubMed
29.
Zurück zum Zitat Glynne-Jones R, Nilsson PJ, Aschele C, et al. European society for medical oncology (ESMO); European society of surgical oncology (ESSO); European society of radiotherapy and oncology (ESTRO). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40(10):1165–76.CrossRefPubMed Glynne-Jones R, Nilsson PJ, Aschele C, et al. European society for medical oncology (ESMO); European society of surgical oncology (ESSO); European society of radiotherapy and oncology (ESTRO). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40(10):1165–76.CrossRefPubMed
30.
Zurück zum Zitat Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol. 1997;15(5):2040–9.CrossRefPubMed Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol. 1997;15(5):2040–9.CrossRefPubMed
31.
Zurück zum Zitat Wright JL, Patil SM, Temple LK, et al. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010;78(4):1064–72.CrossRefPubMed Wright JL, Patil SM, Temple LK, et al. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010;78(4):1064–72.CrossRefPubMed
Metadaten
Titel
Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT
verfasst von
V. Dell’Acqua
J. Kobiela
F. Kraja
M. C. Leonardi
A. Surgo
M. A. Zerella
S. Arculeo
C. Fodor
R. Ricotti
M. G. Zampino
S. Ravenda
G. Spinoglio
R. Biffi
A. Bazani
R. Luraschi
S. Vigorito
P. Spychalski
R. Orecchia
R. Glynne-Jones
B. A. Jereczek-Fossa
Publikationsdatum
01.05.2018
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 5/2018
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-018-1118-3

Weitere Artikel der Ausgabe 5/2018

Medical Oncology 5/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.